A Phase 3 clinical trial evaluating pembrolizumab (Keytruda) as adjuvant therapy for triple-negative breast cancer reached its primary completion on 2026-05-31. The study, which enrolled 1155 participants, aimed to assess how well pembrolizumab works in this patient population.
Background
The study investigated pembrolizumab, an immunotherapy with monoclonal antibodies. This type of therapy is designed to help the body's immune system attack cancer cells and may interfere with the ability of tumor cells to grow and spread. The trial specifically focused on its use as an adjuvant therapy for patients with triple-negative breast cancer.
Trial design
The randomized Phase 3 study, identified as NCT02954874, enrolled 1155 participants. It is evaluating pembrolizumab as an adjuvant therapy for patients diagnosed with triple-negative breast cancer, encompassing conditions such as Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, and Stage III Breast Cancer AJCC v7. The trial's primary completion indicates that data collection for its main objectives has concluded.
What this means
The primary completion of this Phase 3 trial for pembrolizumab in triple-negative breast cancer signifies that the collection of data for the study's main objectives has concluded. While this marks a significant milestone in the trial process, specific efficacy or safety results from the study are not yet available. Clinicians and researchers will need to await the full analysis and publication of these results to understand the potential impact of pembrolizumab as an adjuvant therapy in this challenging cancer type.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The entry for study NCT02954874, titled "Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer", was updated to reflect primary completion on 2026-05-31 on clinicaltrials.gov.